Abstract
Summary
Middle East and Africa genetic testing market is expected to reach USD 1,596,034.48 thousand by 2031 from USD 563,647.94 thousand in 2023 with growing at a CAGR of 14.2% during the forecast period of 2024 to 2031.
Market Segmentation
Middle East and Africa Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), By Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Genetic Testing Market Dynamics
Driver
• Growing prevalence of genetic disorders
Restrain
• High cost of genetic testing
Opportunity
• Strategic initiatives by the key market player
Market Players
Some of the key market players for Middle East and Africa genetic testing market are:
• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Illumina, Inc.
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics
• Myriad Genetics, Inc.
• Abbott
• Eurofins Scientific
• Sorenson Genomics
• BIO-HELIX
• Biocartis
• Cepheid (A subsidiary of Danaher)
• PacBio
• ELITechGroup
• Genes2Me
• Eugene Labs
• Otogenetics
• Mapmygenome
• MedGenome
• BioReference
• Natera, Inc.
Table of Contents
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET 67
1.4 LIMITATIONS 69
1.5 MARKETS COVERED 69
2 MARKET SEGMENTATION 72
2.1 MARKETS COVERED 72
2.2 GEOGRAPHICAL SCOPE 73
2.3 YEARS CONSIDERED FOR THE STUDY 74
2.4 CURRENCY AND PRICING 74
2.5 DBMR TRIPOD DATA VALIDATION MODEL 75
2.6 TYPE LIFELINE CURVE 79
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.8 DBMR MARKET POSITION GRID 81
2.9 MARKET APPLICATION COVERAGE GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 87
4.1 PESTAL ANALYSIS 90
4.2 PORTERS 5 FORCES 91
4.3 EPIDEMIOLOGY 92
5 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: REGULATIONS 93
6 MARKET OVERVIEW 95
6.1 DRIVERS 97
6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 97
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 97
6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 98
6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 98
6.2 RESTRAINTS 99
6.2.1 HIGH COST OF GENETIC TESTING 99
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 100
6.3 OPPORTUNITIES 100
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 100
6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 101
6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 101
6.4 CHALLENGES 102
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 102
6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 103
7 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE 104
7.1 OVERVIEW 105
7.2 DIAGNOSTIC TESTING 109
7.3 PRENATAL TESTING 109
7.3.1 NON-INVASIVE SCREENING 110
- 7.3.1.1 WHOLE GENOME SEQUENCING 111
- 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 111
- 7.3.1.3 OTHERS 111
7.3.2 BY CONDITION 112
- 7.3.2.1 TRISOMY 21 112
- 7.3.2.2 KLINEFELTER SYNDROME 112
- 7.3.2.3 JACOBS SYNDROME 112
- 7.3.2.4 CYSTIC FIBROSIS 112
- 7.3.2.5 TURNER SYNDROME 113
- 7.3.2.6 TRISOMY 18 113
- 7.3.2.7 HEMOPHILIA 113
- 7.3.2.8 TRISOMY 13 113
- 7.3.2.9 MICRODELETION SYNDROME 113
- 7.3.2.10 FETAL GENDER 113
- 7.3.2.11 OTHERS 113
7.3.3 BY SCREENING TYPE 114
- 7.3.3.1 CARRIER SEQUENCING 114
- 7.3.3.2 SEQUENTIAL SEQUENCING 114
7.3.4 MATERNAL SERUM QUAD SCREENING 114
7.4 NEW-BORN SCREENING 115
7.4.1 SICKLE CELL DISEASE 115
7.4.2 CONGENITAL HYPOTHYROIDISM 116
7.4.3 PHENYLKETONURINA (PKU) 116
7.4.4 GALACTOSEMIA 116
7.4.5 MAPLE SYRUP URINE DISEASE 116
7.4.6 OTHERS 116
7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 116
7.6 CARRIER TESTING 117
7.6.1 MOLECULAR SCREENING TEST 117
7.6.2 BIOCHEMICAL SCREENING TEST 118
- 7.6.2.1 EXPANDED CARRIER SCREENING 118
- 7.6.2.2 PREDESIGNED PANEL TESTING 119
- 7.6.2.3 CUSTOM-MADE PANEL TESTING 119
- 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 119
- 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 119
- 7.6.2.4.2 PULMONARY CONDITIONS 120
- 7.6.2.4.3 NEUROLOGICAL CONDITIONS 120
- 7.6.2.4.4 OTHER CONDITIONS 120
7.7 OTHER TYPES 120
8 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY 121
8.1 OVERVIEW 122
8.2 POLYMERASE CHAIN REACTION 125
8.2.1 REAL-TIME PCR (QPCR) 126
8.2.2 DIGITAL PCR (DPCR) 126
8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 126
8.2.4 HOT-START PCR 126
8.2.5 MULTIPLEX PCR 126
8.2.6 OTHER PCR 126
8.3 DNA SEQUENCING (NGS-BASED TESTING) 127
8.3.1 NEXT GENERATION SEQUENCING (NGS) 127
8.3.2 SANGER SEQUENCING (SINGLE GENE) 127
8.3.3 OTHER 128
8.4 WHOLE GENOME SEQUENCING 128
8.5 MICROARRAYS 128
8.5.1 DNA MICROARRAYS 129
8.5.2 PROTEIN MICROARRAYS 129
8.5.3 OTHER MICROARRAYS 129
8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 129
8.7 OTHERS 130
9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY DISEASES 131
9.1 OVERVIEW 132
9.2 CANCER 135
9.2.1 BREAST 136
9.2.2 COLON 136
9.2.3 LUNG 136
9.2.4 PROSTATE 136
9.2.5 OTHERS 136
9.3 SICKLE CELL ANEMIA 137
9.4 THALASSEMIA 137
9.5 RARE GENETIC DISORDER 138
9.5.1 TRISOMY 21 138
9.5.2 MONOSOMY X 138
9.5.3 TRISOMY 13 139
9.5.4 MICRODELETION SYNDROME 139
9.5.5 TRISOMY 18 139
9.5.6 OTHERS 139
9.6 FRAGILE X SYNDROME 139
9.7 DUCHENNE MUSCULAR DYSTROPHY 140
9.8 HUNTINGTON'S DISEASE 140
9.9 CYSTIC FIBROSIS 141
9.10 OTHERS 141
10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER 142
10.1 OVERVIEW 143
10.2 HOSPITALS 146
10.3 CLINICS 147
10.4 DIAGNOSTIC CENTERS 147
10.5 PRIVATE CLINICS 148
10.6 LABORATORY SERVICE PROVIDERS 148
10.7 PRIVATE LABORATORIES 149
11 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY REGION 150
11.1 MIDDLE EAST AND AFRICA 152
11.1.1 SOUTH AFRICA 162
11.1.2 SAUDI ARABIA 173
11.1.3 U.A.E 184
11.1.4 ISRAEL 195
11.1.5 EGYPT 206
11.1.6 REST OF MIDDLE EAST AND AFRICA 217
12 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 218
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 218
13 SWOT ANALYSIS 219
14 COMPANY PROFILES 220
14.1 ILLUMINA, INC 220
14.1.1 COMPANY SNAPSHOT 220
14.1.2 REVENUE ANALYSIS 220
14.1.3 COMPANY SHARE ANALYSIS 221
14.1.4 PRODUCT PORTFOLIO 221
14.1.5 RECENT DEVELOPMENT 222
14.2 CEPHEID 223
14.2.1 COMPANY SNAPSHOT 223
14.2.2 REVENUE ANALYSIS 223
14.2.3 COMPANY SHARE ANALYSIS 224
14.2.4 PRODUCT PORTFOLIO 224
14.2.5 RECENT DEVELOPMENT 224
14.3 FULGENT GENETICS 225
14.3.1 COMPANY SNAPSHOT 225
14.3.2 REVENUE ANALYSIS 225
14.3.3 COMPANY SHARE ANALYSIS 226
14.3.4 PRODUCT PORTFOLIO 226
14.3.5 RECENT DEVELOPMENT 227
14.4 PERKINELMER INC 228
14.4.1 COMPANY SNAPSHOT 228
14.4.2 REVENUE ANALYSIS 228
14.4.3 COMPANY SHARE ANALYSIS 229
14.4.4 PRODUCT PORTFOLIO 229
14.4.5 RECENT DEVELOPMENT 229
14.5 THERMO FISHER SCIENTIFIC INC 230
14.5.1 COMPANY SNAPSHOT 230
14.5.2 REVENUE ANALYSIS 230
14.5.3 COMPANY SHARE ANALYSIS 231
14.5.4 PRODUCT PORTFOLIO 231
14.5.5 RECENT DEVELOPMENT 232
- 14.5.5.1 COLLABORATION 232
14.6 BIOREFERENCE 233
14.6.1 COMPANY SNAPSHOT 233
14.6.2 REVENUE ANALYSIS 233
14.6.3 PRODUCT PORTFOLIO 234
14.6.4 RECENT DEVELOPMENT 234
14.7 ELITECHGROUP 235
14.7.1 COMPANY SNAPSHOT 235
14.7.2 PRODUCT PORTFOLIO 235
14.7.3 RECENT DEVELOPMENTS 236
14.8 EUROFINS SCIENTIFIC 237
14.8.1 COMPANY SNAPSHOT 237
14.8.2 REVENUE ANALYSIS 237
14.8.3 PRODUCT PORTFOLIO 238
14.8.4 RECENT DEVELOPMENT 238
14.9 INVITAE CORPORATION 239
14.9.1 COMPANY SNAPSHOT 239
14.9.2 REVENUE ANALYSIS 239
14.9.3 PRODUCT PORTFOLIO 240
14.9.4 RECENT DEVELOPMENTS 240
14.10 MYRIAD GENETICS 241
14.10.1 COMPANY SNAPSHOT 241
14.10.2 REVENUE ANALYSIS 241
14.10.3 PRODUCT PORTFOLIO 242
14.10.4 RECENT DEVELOPMENT 242
14.11 ABBOTT 243
14.11.1 COMPANY SNAPSHOT 243
14.11.2 REVENUE ANALYSIS 243
14.11.3 PRODUCT PORTFOLIO 244
14.11.4 RECENT DEVELOPMENT 244
14.12 BIOCARTIS 245
14.12.1 COMPANY SNAPSHOT 245
14.12.2 REVENUE ANALYSIS 245
14.12.3 PRODUCT PORTFOLIO 246
14.12.4 RECENT DEVELOPMENTS 246
- 14.12.4.1 PARTNERSHIP 246
14.13 BIO-HELIX 247
14.13.1 COMPANY SNAPSHOT 247
14.13.2 PRODUCT PORTFOLIO 247
14.13.3 RECENT DEVELOPMENT 247
14.14 BIO-RAD LABORATORIES, INC 248
14.14.1 COMPANY SNAPSHOT 248
14.14.2 REVENUE ANALYSIS 248
14.14.3 PRODUCT PORTFOLIO 249
14.14.4 RECENT DEVELOPMENTS 249
14.15 EUGENE LABS 250
14.15.1 COMPANY SNAPSHOT 250
14.15.2 PRODUCT PORTFOLIO 250
14.15.3 RECENT DEVELOPMENT 250
14.16 F. HOFFMANN-LA ROCHE LTD 251
14.16.1 COMPANY SNAPSHOT 251
14.16.2 REVENUE ANALYSIS (PARENT COMPANY) 251
14.16.3 PRODUCT PORTFOLIO 252
14.16.4 RECENT DEVELOPMENT 252
14.17 GENES2ME 253
14.17.1 COMPANY SNAPSHOT 253
14.17.2 PRODUCT PORTFOLIO 253
14.17.3 RECENT DEVELOPMENT 253
14.18 MAPMYGENOME 254
14.18.1 COMPANY SNAPSHOT 254
14.18.2 PRODUCT PORTFOLIO 254
14.18.3 RECENT DEVELOPMENT 255
14.19 MEDGENOME 256
14.19.1 COMPANY SNAPSHOT 256
14.19.2 PRODUCT PORTFOLIO 256
14.19.3 RECENT DEVELOPMENT 257
14.20 NATERA, INC 258
14.20.1 COMPANY SNAPSHOT 258
14.20.2 REVENUE ANALYSIS 258
14.20.3 PRODUCT PORTFOLIO 259
14.20.4 RECENT DEVELOPMENT 260
14.21 OTOGENETICS 261
14.21.1 COMPANY SNAPSHOT 261
14.21.2 PRODUCT PORTFOLIO 262
14.21.3 RECENT DEVELOPMENT 262
14.22 PACBIO 263
14.22.1 COMPANY SNAPSHOT 263
14.22.2 REVENUE ANALYSIS 263
14.22.3 PRODUCT PORTFOLIO 264
14.22.4 RECENT DEVELOPMENT 264
14.23 QIAGEN 265
14.23.1 COMPANY SNAPSHOT 265
14.23.2 REVENUE ANALYSIS 265
14.23.3 PRODUCT PORTFOLIO 266
14.23.4 RECENT DEVELOPMENT 266
14.24 SORENSON GENOMICS 267
14.24.1 COMPANY SNAPSHOT 267
14.24.2 PRODUCT PORTFOLIO 267
14.24.3 RECENT DEVELOPMENT 267
15 QUESTIONNAIRE 268
16 RELATED REPORTS 271